Tonix Pharmaceuticals Holding (TNXP) said Friday it received a patent from the US Patent and Trademark Office for its pre-filled autoinjector comprising of Zembrace SymTouch composition to treat migraines.
The patent is anticipated to expire in 2036, excluding potential extensions, the biopharmaceutical company added.
Zembrace is a US Food and Drug Administration-approved treatment for migraines, Tonix said.
Shares of the company rose 23% in recent Friday premarket activity.
Price: 0.1685, Change: +0.03, Percent Change: +23.35
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。